Bird Fancier's Lung: Treatment Protocol After Systemic Corticosteroids Failed to Control Inflammatory Hypersensitivity Pneumonitis
This protocol covers the next step for patients with Bird fancier's lung presenting as nonfibrotic (inflammatory) hypersensitivity pneumonitis whose disease was not adequately controlled after an initial course of systemic corticosteroids.
Nonfibrotic inflammatory hypersensitivity pneumonitis
The patient has hypersensitivity pneumonitis with features of inflammation — ground-glass opacities on HRCT, bronchoalveolar lavage lymphocytosis, or well-documented avian antigen exposure with acute or sub-acute symptom onset — and an absence of pulmonary fibrosis. International guidelines recommend classifying HP as fibrotic or nonfibrotic, as the presence or absence of fibrosis carries distinct prognostic and treatment implications.
Prior line: systemic corticosteroids
The previous step — moderate-to-high dose systemic corticosteroids (with intravenous methylprednisolone for rapid-onset presentations with severe physiologic compromise) — did not achieve improvement or stabilization in clinical symptoms and lung function (FVC) when re-assessed between 6 and 12 weeks. This protocol is the next step taken after that failure.
Treatment direction
The strategy involves adding a steroid-sparing immunosuppressive agent to allow weaning of corticosteroids while sustaining therapeutic benefit. The specific agent selection, sequencing, and full management algorithm are available in the complete protocol.
Clinical targets include improvement in symptoms and lung function parameters (FVC, DLCO), or at minimum stabilization of disease.
References
DOI: 10.1111/resp.14847
Moderate-to-high dose systemic corticosteroids would usually be considered for HP patients with features of inflammation (e.g., GGO on HRCT, BAL lymphocytosis, well-documented exposure with acute or sub-acute symptom onset).
Recently published international diagnostic guidelines recommend HP classification into fibrotic or nonfibrotic phenotypes based on the presence or absence of radiological and/or histopathological fibrosis, supported by the observation that pulmonary fibrosis conveys important prognostic and treatment implications.
A steroid-sparing agent (e.g., mycophenolate mofetil (MMF), azathioprine, cyclophosphamide, rituximab) may enable weaning of corticosteroids and maintenance of therapeutic benefit.
Second-line immunosuppressive agents (MMF, azathioprine, methotrexate) have not been compared head-to-head, and so the choice of agent is often guided by potential side effects and clinician experience.
For nonfibrotic HP, improvement in clinical parameters with therapy may be expected, whereas disease stabilization (or slowing of progression) may be more realistic goals in patients with predominantly fibrotic HP.
View source ↗